GoodGirlRX: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://goodgirlrx.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   ““FDA-approved meds.””

2. 2

   ““FDA-approved options””

3. 3

   ““Clinically proven GLP-1 results””

4. 4

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

goodgirlrx.com returned a live storefront when we checked in August 2026, advertising a first-month price and covering weight loss, hormone therapy, anti-ageing and wellness for women. We did not review every page on the site.

Most of these letters require you to follow an inference — same ingredient, therefore same product, therefore same approval. This one skips the chain. "FDA-approved meds." is a two-word assertion about regulatory status, and compounded semaglutide and tirzepatide do not have that status, which is why it was cited. That makes this a good page to read first if you are new to the topic, because there is nothing subtle to argue about. It also makes the pricing point simple. A first-month promotional price sitting under the words "FDA-approved" invites you to think you are getting an approved medicine at a discount. You are being offered a compounded preparation at a compounded price. That may still be the right purchase for you — the letter makes no finding about the product or the company's care — but you should make it knowing which of the two things you are buying.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence GoodGirlRX failed to respond.